Potential role of acetylsalicilic acid and other non-steroidal anti-inflammatory drugs in cancer risk reduction (literature review)
DOI:
https://doi.org/10.14739/2310-1210.2021.3.209851Keywords:
acetylsalicylic acid, non-steroidal anti-inflammatory drugs, cancer riskAbstract
The aim of this review is to analyze and summarize the existing evidence regarding the possibilities of using acetylsalicylic acid (ASA) and other non-steroidal anti-inflammatory drugs (NSAIDs) to reduce cancer risk.
Conclusions. Chronic inflammation facilitates the onset and progress of tumour growth. Anti-cancer properties of acetylsalicylic acid and other non-steroidal anti-inflammatory drugs are mediated via cyclooxygenase COX-dependent mechanisms, as well as other tumorigenic pathways. Current systematic review addresses potential role of ASA and other NSAIDs in reduction of cancer risk for the following localizations: head and neck, lungs, gastrointestinal tract, breast, ovaries, prostate, and skin. The role of ASA in primary prevention of colorectal cancer in specific populations is presented in 2016 U. S. Preventive Services Task Force guidelines. Studies indicate heterogeneous protective potential of ASA against different cancer types, depending on studied population, duration of intake and dose. Influence of non-aspirin NSAIDs on cancer morbidity and mortality is more controversial.
References
Khandia, R., & Munjal, A. (2020). Chapter Six - Interplay between inflammation and cancer. In R. Donev (Ed.), Advances in protein chemistry and structural biology (Vol. 119, pp. 199-245). Academic Press. https://doi.org/10.1016/bs.apcsb.2019.09.004
Baron, J. A. (2003). Epidemiology of non-steroidal anti-inflammatory drugs and cancer. In A. J. Dannenberg & R. N. DuBois (Eds.), Progress in Experimental Tumor Research (Vol. 37, pp. 1-24). Basel, Karger. https://doi.org/10.1159/000071364
Zappavigna, S., Cossu, A. M., Grimaldi, A., Bocchetti, M., Ferraro, G. A., Nicoletti, G. F., Filosa, R., & Caraglia, M. (2020). Anti-Inflammatory Drugs as Anticancer Agents. International Journal of Molecular Sciences, 21(7), Article 2605. https://doi.org/10.3390/ijms21072605
Usman, M. W., Luo, F., Cheng, H., Zhao, J. J., & Liu, P. (2015). Chemopreventive effects of aspirin at a glance. Biochimica et Biophysica Acta, 1855(2), 254-263. https://doi.org/10.1016/j.bbcan.2015.03.007
Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews Cancer, 11(2), 123-134. https://doi.org/10.1038/nrc3004
Schrör, K., & Rauch, B. H. (2013). Acetylsalicylsäure und Prävention kolorektaler Karzinome. Der Internist, 54(7), 884-891. https://doi.org/10.1007/s00108-013-3311-y
Saxena, P., Sharma, P. K., & Purohit, P. (2020). A journey of celecoxib from pain to cancer. Prostaglandins & Other Lipid Mediators, 147, Article 106379. https://doi.org/10.1016/j.prostaglandins.2019.106379
Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015). Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology, 149(7), 1884-1895.e4. https://doi.org/10.1053/j.gastro.2015.07.064
Tołoczko-Iwaniuk, N., Dziemiańczyk-Pakieła, D., Nowaszewska, B. K., Celińska-Janowicz, K., & Miltyk, W. (2019). Celecoxib in Cancer Therapy and Prevention - Review. Current Drug Targets, 20(3), 302-315. https://doi.org/10.2174/1389450119666180803121737
Vallée, A., Lecarpentier, Y., & Vallée, J. N. (2019). Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs. Cells, 8(7), Article 726. https://doi.org/10.3390/cells8070726
Tsoi, K., Ho, J., Chan, F., & Sung, J. (2019). Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. International Journal of Cancer, 145(1), 267-273. https://doi.org/10.1002/ijc.32083
Loomans-Kropp, H. A., Pinsky, P., Cao, Y., Chan, A. T., & Umar, A. (2019). Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. JAMA Network Open, 2(12), Article e1916729. https://doi.org/10.1001/jamanetworkopen.2019.16729
McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., Kirpach, B., Shah, R. C., Ives, D. G., Storey, E., Ryan, J., Tonkin, A. M., Newman, A. B., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., Orchard, S. G., … ASPREE Investigator Group. (2018). Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. The New England Journal of Medicine, 379(16), 1519-1528. https://doi.org/10.1056/NEJMoa1803955
Zheng, S. L., & Roddick, A. J. (2019). Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA, 321(3), 277-287. https://doi.org/10.1001/jama.2018.20578
de la Cour, C. D., Dehlendorff, C., Aalborg, G. L., von Buchwald, C., Friis, S., Verdoodt, F., & Kjaer, S. K. (2020). Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study. International Journal of Cancer, 146(8), 2139-2146. https://doi.org/10.1002/ijc.32544
Brusselaers, N., & Lagergren, J. (2018). Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open, 8(7), Article e021869. https://doi.org/10.1136/bmjopen-2018-021869
Drew, D. A., Cao, Y., & Chan, A. T. (2016). Aspirin and colorectal cancer: the promise of precision chemoprevention. Nature Reviews Cancer, 16(3), 173-186. https://doi.org/10.1038/nrc.2016.4
Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., Chaussade, S., & Baron, J. A. (2009). Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. Journal of the National Cancer Institute, 101(4), 256-266. https://doi.org/10.1093/jnci/djn485
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. (1993). Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis. The New England Journal of Medicine, 328(18), 1313-1316. https://doi.org/10.1056/NEJM199305063281805
Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010). Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet, 376(9754), 1741-1750. https://doi.org/10.1016/S0140-6736(10)61543-7
Cao, Y., Nishihara, R., Wu, K., Wang, M., Ogino, S., Willett, W. C., Spiegelman, D., Fuchs, C. S., Giovannucci, E. L., & Chan, A. T. (2016). Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncology, 2(6), 762-769. https://doi.org/10.1001/jamaoncol.2015.6396
Friis, S., Riis, A. H., Erichsen, R., Baron, J. A., & Sørensen, H. T. (2015). Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. Annals of Internal Medicine, 163(5), 347-355. https://doi.org/10.7326/M15-0039
Veettil, S. K., Nathisuwan, S., Ching, S. M., Jinatongthai, P., Lim, K. G., Kew, S. T., & Chaiyakunapruk, N. (2019). Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis. Cancer Management and Research, 11, 561-571. https://doi.org/10.2147/CMAR.S180261
(2016). Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force. Annals of Internal Medicine, 164(12), 1-22. https://doi.org/10.7326/P16-9015
Emilsson, L., Holme, Ø., Bretthauer, M., Cook, N. R., Buring, J. E., Løberg, M., Adami, H. O., Sesso, H. D., Gaziano, M. J., & Kalager, M. (2017). Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Alimentary Pharmacology & Therapeutics, 45(2), 193-204. https://doi.org/10.1111/apt.13857
Nan, H., Hutter, C. M., Lin, Y., Jacobs, E. J., Ulrich, C. M., White, E., Baron, J. A., Berndt, S. I., Brenner, H., Butterbach, K., Caan, B. J., Campbell, P. T., Carlson, C. S., Casey, G., Chang-Claude, J., Chanock, S. J., Cotterchio, M., Duggan, D., Figueiredo, J. C., Fuchs, C. S., … GECCO. (2015). Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants. JAMA, 313(11), 1133-1142. https://doi.org/10.1001/jama.2015.1815
Song, Y., Zhong, X., Gao, P., Zhou, C., Shi, J., Wu, Z., Guo, Z., & Wang, Z. (2020). Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review. Frontiers in Endocrinology, 11, Article 3. https://doi.org/10.3389/fendo.2020.00003
Simon, T. G., Ma, Y., Ludvigsson, J. F., Chong, D. Q., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., Zhang, X., & Chan, A. T. (2018). Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology, 4(12), 1683-1690. https://doi.org/10.1001/jamaoncol.2018.4154
Sun, J., Li, Y., Liu, L., Jiang, Z., & Liu, G. (2019). Aspirin use and pancreatic cancer risk: A systematic review of observational studies. Medicine, 98(51), Article e18033. https://doi.org/10.1097/MD.0000000000018033
Yokoyama, K., Ishizuka, N., Uemura, N., Mizokami, Y., Hiraishi, H., Murata, M., Uchiyama, S., Teramoto, T., Shimada, K., Yamazaki, T., Oikawa, S., Sugawara, M., Ando, K., Ikeda, Y., & JPPP study group. (2018). Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese. Research and Practice in Thrombosis and Haemostasis, 2(2), 274-281. https://doi.org/10.1002/rth2.12097
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7-30. https://doi.org/10.3322/caac.21442
Hochmuth, F., Jochem, M., & Schlattmann, P. (2016). Meta-analysis of aspirin use and risk of lung cancer shows notable results. European Journal of Cancer Prevention, 25(4), 259-268. https://doi.org/10.1097/CEJ.0000000000000176
Zhang, W., Yi, L., Shen, J., Zhang, H., Luo, P., & Zhang, J. (2020). Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis. Journal of Cancer, 11(7), 1816-1827. https://doi.org/10.7150/jca.35003
Yi, L., Zhang, W., Zhang, H., Shen, J., Zou, J., Luo, P., & Zhang, J. (2018). Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer. Drug Design, Development and Therapy, 12, 2455-2466. https://doi.org/10.2147/DDDT.S169627
Lu, L., Shi, L., Zeng, J., & Wen, Z. (2017). Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget, 8(25), 40389-40401. https://doi.org/10.18632/oncotarget.16315
Kehm, R. D., Hopper, J. L., John, E. M., Phillips, K. A., MacInnis, R. J., Dite, G. S., Milne, R. L., Liao, Y., Zeinomar, N., Knight, J. A., Southey, M. C., Vahdat, L., Kornhauser, N., Cigler, T., Chung, W. K., Giles, G. G., McLachlan, S. A., Friedlander, M. L., Weideman, P. C., Glendon, G., … Terry, M. B. (2019). Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research, 21(1), Article 52. https://doi.org/10.1186/s13058-019-1135-y
Zhang, S. M., Cook, N. R., Manson, J. E., Lee, I. M., & Buring, J. E. (2008). Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. British Journal of Cancer, 98(5), 989-991. https://doi.org/10.1038/sj.bjc.6604240
Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., Hicks, J., Makris, A., Evans, A., Loibl, S., Denkert, C., Murray, E., Grieve, R., Coleman, R., Schmidt, M., Klare, P., Rezai, M., Rautenberg, B., Klutinus, N. … Bliss, J. (2018). Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). Abstracts: 2017 San Antonio Breast Cancer Symposium December 5-9 (Vol. 78, Issue 4, pp. GS3-03). https://doi.org/10.1158/1538-7445.sabcs17-gs3-03
Busby, J., Murray, L., Mills, K., Zhang, S. D., Liberante, F., & Cardwell, C. R. (2018). A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties. Pharmacoepidemiology & Drug Safety, 27(1), 78-86. https://doi.org/10.1002/pds.4345
Zhang, D., Bai, B., Xi, Y., Wang, T., & Zhao, Y. (2016). Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecologic Oncology, 142(2), 368-377. https://doi.org/10.1016/j.ygyno.2016.04.543
Hannibal, C. G., Dehlendorff, C., & Kjaer, S. K. (2018). Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark. Gynecologic Oncology, 151(3), 513-518. https://doi.org/10.1016/j.ygyno.2018.09.022
Verdoodt, F., Dehlendorff, C., Friis, S., & Kjaer, S. K. (2018). Non-aspirin NSAID use and ovarian cancer mortality. Gynecologic Oncology, 150(2), 331-337. https://doi.org/10.1016/j.ygyno.2018.06.018
Thapa, D., & Ghosh, R. (2015). Chronic inflammatory mediators enhance prostate cancer development and progression. Biochemical Pharmacology, 94(2), 53-62. https://doi.org/10.1016/j.bcp.2014.12.023
Shang, Z., Wang, X., Yan, H., Cui, B., Wang, Q., Wu, J., Cui, X., Li, J., Ou, T., & Yang, K. (2018). Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis. Frontiers in Oncology, 8, Article 437. https://doi.org/10.3389/fonc.2018.00437
Hurwitz, L. M., Joshu, C. E., Barber, J. R., Prizment, A. E., Vitolins, M. Z., Jones, M. R., Folsom, A. R., Han, M., & Platz, E. A. (2019). Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case Fatality in the Atherosclerosis Risk in Communities Study. Cancer Epidemiology, Biomarkers & Prevention, 28(3), 563-569. https://doi.org/10.1158/1055-9965.EPI-18-0965
Zhou, J., Xia, S., Li, T., & Liu, R. (2019). Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis. BMC Cancer, 19(1), Article 1186. https://doi.org/10.1186/s12885-019-6415-5
Muranushi, C., Olsen, C. M., Pandeya, N., & Green, A. C. (2015). Aspirin and Nonsteroidal Anti-Inflammatory Drugs Can Prevent Cutaneous Squamous Cell Carcinoma: a Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 135(4), 975-983. https://doi.org/10.1038/jid.2014.531
Ma, Y., Yu, P., Lin, S., Li, Q., Fang, Z., & Huang, Z. (2020). The association between nonsteroidal anti-inflammatory drugs and skin cancer: Different responses in American and European populations. Pharmacological Research, 152, Article 104499. https://doi.org/10.1016/j.phrs.2019.104499
Johannesdottir, S. A., Chang, E. T., Mehnert, F., Schmidt, M., Olesen, A. B., & Sørensen, H. T. (2012). Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer, 118(19), 4768-4776. https://doi.org/10.1002/cncr.27406
Elmets, C. A., Viner, J. L., Pentland, A. P., Cantrell, W., Lin, H. Y., Bailey, H., Kang, S., Linden, K. G., Heffernan, M., Duvic, M., Richmond, E., Elewski, B. E., Umar, A., Bell, W., & Gordon, G. B. (2010). Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the National Cancer Institute, 102(24), 1835-1844. https://doi.org/10.1093/jnci/djq442
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
